BioCryst Pharmaceuticals, Inc. - Common Stock (BCRX)

BioCryst Pharmaceuticals raised its 2025 revenue and expense forecasts, projecting net income and positive cash flow for the year.

BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.

BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.

BCRX earnings call for the period ending December 31, 2024.

BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.

BCRX earnings call for the period ending September 30, 2024.

BCRX earnings call for the period ending June 30, 2024.

Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling.

A better-than-expected first quarter and a goal of profitability and positive cash flow by the end of 2025 brought on a bit of a rally.

BCRX earnings call for the period ending March 31, 2024.

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by Orladeyo revenue growth. With strong patient demand and strategic initiatives, BioCryst projects robust revenue

BCRX stock results show that BioCryst Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

These penny stocks offer triple digit returns to investors right now but not many investors are aware of them.

BCRX earnings call for the period ending December 31, 2023.

BioCryst reported quarterly losses of 28 cents per share, missing the analyst consensus estimate of losses of 24 cents by 16.67% and representing a 26.32% increase over losses of 38 cents per share from the same period last year. The company reported quarterly sales of $93.4 million which beat the analyst consensus estimate of $90.01 million by 3.77% and is a 17.42% increase over sales of $79.55 million from the prior year's quarter.